News | July 17, 2009

Medtronic SureScan Pacing Systems Enable Patients to Access Key Imaging Diagnostics

July 17, 2009 – Medtronic announced today the first enrollments in a magnetic resonance imaging (MRI) substudy of the global PANORAMA registry.

Dr. Raed Sweidan, consultant electrophysiologist and head of the EP Department at King Fahd Armed Forces Hospital in Jeddah, Saudi Arabia, enrolled the first patient, who received a Medtronic EnRhythm MRI SureScan pacing system.

The EnRhythm MRI and Advisa MRI SureScan pacing systems enable patients to access MRI scans. The EnRhythm MRI and Advisa MRI SureScan pacing systems are not currently available for sale in the U.S., and no U.S. patients will be enrolled in the substudy.

The PANORAMA registry is collecting long-term product performance data on all types of Medtronic cardiac rhythm disease management devices implanted outside the U.S., including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy devices (CRTs), leads and insertable cardiac monitors (ICMs). For more than 25 years, Medtronic has published twice-annual product performance reports. The latest report, the 2009 First Edition, Issue 60, includes data applicable to more than 13.8 million implanted cardiac devices and leads worldwide.

The PANORAMA registry was initiated in 2005 and will involve 10,000 patients at 150 centers in 33 countries on four continents. PANORAMA parallels both the company's System Longevity Study (SLS) and OMNI study in the U.S. In addition to long-term device surveillance, PANORAMA is assessing adherence to and adoption of medical society practice guidelines for implanted cardiac devices.

The MRI substudy will involve up to 1,500 patients at 120 centers as part of the ongoing PANORAMA initiative and will collect MRI-related epidemiological data on patients outside the U.S. who have received a market-approved Medtronic pacing system for use with MRI machines, the EnRhythm MRI SureScan or Advisa MRI SureScan pacing systems; the referral process for patients who require an MRI scan; and long-term data on system performance, as well as system performance when exposed to MRI scans, among others.

For more information: www.medtronic.com


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now